Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: A meta-analysis of randomized clinical trials

被引：8

作者：

Le Nguyen M.-T. ^{[1
]}

Spencer F.A. ^{[1
]}

机构：

[1] Cardiovasc. Thromb. Res. Center, Department of Medicine, University of Massachusetts, Worcester

来源：

Journal of Thrombosis and Thrombolysis | 2001年 / 12卷 / 3期

关键词：

Acute coronary syndromes; Clinical outcomes; Low molecular weight heparin;

D O I：

10.1023/A:1015287311065

中图分类号：

学科分类号：

摘要：

Background: The standard of care in Acute Coronary Syndromes (ACS) includes a full complement of antischemic and antithrombotic therapy. Although aspirin is used widely and concomitant anticoagulation is recommended, the comparative benefits of low molecular weight heparin (LMWH) and unfractionated heparin (UFH) have not been defined. Methods/results: A meta-analysis including all randomized clinical trials comparing LMWH and UFH for the treatment of non-ST segment elevation acute coronary syndromes was performed. Risk ratios (RR), using the DerSimonian-Laird Model, were calculated from a total of 13,320 patients. Death (RR 0.98, 95% CI 0.73-1.31), death and myocardial infarction (MI) (RR 0.86, 95% CI 0.74-1.01), death, MI, recurrent angina or revascularization (RR 0.89, 95% CI 0.74-1.07) and major hemorrhage (RR 1.01, 95% CI 0.81-1.25) occurred with similar frequencies for the anticoagulant-based strategies. Conclusions: Fixed dose LMWH therapy given subcutaneously compares favorably with UFH titrated to a target level of anticoagulation and should be considered a safe, effective, and clinically acceptable alternative in the early management of patients with non-ST segment elevation ACS. The superiority of LMWH preparations characterized by high in vitro factor Xa to thrombin inhibitory capacity is supported by clinic trial data but requires further investigation.

引用

页码：289 / 295

页数：6

共 30 条

[1]

Turpie A., Pharmacology of the low-molecular-weight heparins, Am Heart J, 135, (1998)

[2]

Becker R.C., Bovill E.G., Seghatchian M.J., Samama M., Pathophysiology of thrombin in acute coronary syndromes, Am Heart J, 136, (1998)

[3]

Oler A., Whooley M.A., Oler J., Grady D., Adding herapin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis, JAMA, pp. 811-815, (1996)

[4]

Fareed J., Hoppensteadt D., Jeske W., Et al., The available low molecular weight heparin preparations are not the same, Clin Appl Thrombosis/Hemostasis, 3, SUPPL., (1997)

[5]

Hirish J., Warkentin T.E., Raschke R., Et al., Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety, Chest, 114, (1998)

[6]

Fuster V., Mechanisms of arterial thrombosis. Foundation for therapy, Am Heart J, 135, (1998)

[7]

Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliot G., Lerner R.G., Hall J., Sparling T., Brettell H.R., Norton J., Carter C.J., George R., Merli G., Ward J., Mayo W., Rosenbloom D., Brant R., Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis, N Engl J Med, 326, pp. 975-982, (1992)

[8]

Levine M., Gent M., Herish J., Leclerd J., Anderson D., Weitz J., Ginsberg J., Turpie A.G., Demers C., Kovacs M., Geerts W., Kassis J., Desjardins L., Cusson J., Cruickshank M., Powers P., Brien W., Haley S., Willan A., A comparison of low-molecular-weight heparin administrated primarily at home with UFH administered in the hospital for proximal deep vein thrombosis, N Engl J Med, 334, pp. 667-681, (1996)

[9]

Koopoman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M., Van Der Meer J., Gallus A.S., Simonneau G., Chesterman C.H., Prins M.H., Bossuyt P.M.M., De Haes H., Van Den Belt A.G.M., Sagnard L., D'Azemar P., Buller H.R., Treatment of venous thrombosis with intravenous UFH administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home, N Engl J Med, 334, pp. 682-687, (1996)

[10]

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism, N Engl J Med, 337, pp. 657-662, (1997)

← 1 2 3 →